Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
← catalyst calendarNCT05702229 · readout in 468 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
163estimated
Sites
44
Countries
China, Japan, South Korea +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-16 | actual | When the study began enrolling |
| Primary completion | 2027-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-05-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-01-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Gastric Cancer
Interventions
- Drug: Rilvegostomig
- Drug: Volrustomig
- Drug: FOLFOX
- Drug: XELOX
- Drug: AZD0901
- Drug: 5-Fluorouracil
- Drug: Capecitabine
Primary outcomes
what the primary-completion date above is the date OFORR (per RECIST 1.1 as assessed by Investigator)
measured Through substudy completion, an average of 2 years
PFS6 (per RECIST 1.1 as assessed by Investigator)
measured Through substudy completion, an average of 2 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed